v3.26.3
Stockholders’ Equity (Deficiency)
 9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Stockholders’ Equity (Deficiency) Stockholders’ Equity (Deficiency)
Accumulated Other Comprehensive Loss
Changes in accumulated other comprehensive loss by component were as follows (in thousands):
Foreign
currency
translation
adjustments		Unrealized (loss) gain on cash
flow hedge, net
of tax		OtherAccumulated
other
comprehensive loss
December 31, 2025$(90,545)$(14,844)$(5,340)$(110,729)
Other comprehensive (loss) gain before reclassification(13,332)28,019 4,228 18,915 
Reclassification of cash flow hedge to earnings, net of tax of $0
— 8,730 — 8,730 
September 30, 2026$(103,877)$21,905 $(1,112)$(83,084)
December 31, 2024$(71,860)$6,350 $— $(65,510)
Other comprehensive loss before reclassification(15,648)(23,011)— (38,659)
Reclassification of cash flow hedge to earnings, net of tax of $0
— (1,714)— (1,714)
September 30, 2025$(87,508)$(18,375)$— $(105,883)
Rondo Redeemable Non-Controlling Interests
Beginning January 1, 2026, the holders of the Rondo Class B Units, as defined and discussed in Note 20. Stockholders’ (Deficiency) Equity to the Company’s 2025 Annual Report on Form 10-K, have a put right to require the Company to purchase their units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization, subject to the satisfaction of certain financial targets and other conditions. 
On September 15, 2026, the Company entered into an equity purchase agreement to acquire a portion of the outstanding Rondo Class B Units for cash consideration of $19.8 million. Based on the terms of the agreement, the Company concluded that redemption of the related redeemable non-controlling interest was probable and, as of September 30, 2026, accreted the non-controlling interest to its redemption value, resulting in $14.2 million of accretion during the three and nine months ended September 30, 2026. The Company evaluated the remaining outstanding Rondo Class B Units and concluded that redemption was not probable; accordingly, no additional accretion was recognized. The transaction closed on October 1, 2026 and increased the Company's ownership interest in Rondo from approximately 65.1% to 66.4%.
Acquisition of Non-Controlling Interests in Amneal Complex Products Research LLC
The Company acquired a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), now known as Amneal Complex Products Research LLC (“CPR”), on April 2, 2021. On May 31, 2026, the Company acquired the remaining 2% non-controlling interests in CPR from the sellers of KSP, who are related parties, for cash consideration of $0.4 million. The carrying value of the acquired non-controlling interest was $0.6 million. Following the acquisition, CPR became a wholly owned subsidiary of the Company.
Shares Issued in Connection with the Kashiv Acquisition
On August 10, 2026, the Company issued 28.9 million shares of its Class A common stock to the sellers of Kashiv as the equity portion of the preliminary purchase consideration for the Kashiv Acquisition. Refer to Note 2. Acquisition for additional information about the acquisition and preliminary purchase consideration.